BioCryst Pharmaceuticals, Inc.
BCRX
$9.81
$0.657.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 874.84M | 599.82M | 557.51M | 503.49M | 450.71M |
| Total Other Revenue | -- | 7.35M | 8.11M | 9.16M | 13.05M |
| Total Revenue | 874.84M | 599.82M | 557.51M | 503.49M | 450.71M |
| Cost of Revenue | 180.93M | 189.15M | 186.65M | 179.79M | 185.71M |
| Gross Profit | 693.91M | 410.67M | 370.86M | 323.70M | 265.01M |
| SG&A Expenses | 346.61M | 333.31M | 315.40M | 289.26M | 266.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 527.53M | 522.46M | 502.05M | 469.05M | 451.99M |
| Operating Income | 347.30M | 77.36M | 55.46M | 34.44M | -1.28M |
| Income Before Tax | 267.39M | -6.62M | -32.19M | -51.18M | -86.95M |
| Income Tax Expenses | 3.53M | 2.16M | 3.52M | 2.29M | 1.93M |
| Earnings from Continuing Operations | 263.86 | -8.78 | -35.71 | -53.47 | -88.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 263.86M | -8.78M | -35.71M | -53.47M | -88.88M |
| EBIT | 347.30M | 77.36M | 55.46M | 34.44M | -1.28M |
| EBITDA | 348.69M | 78.66M | 56.74M | 35.71M | -33.00K |
| EPS Basic | 1.25 | -0.04 | -0.17 | -0.26 | -0.43 |
| Normalized Basic EPS | 0.86 | 0.00 | -0.08 | -0.15 | -0.26 |
| EPS Diluted | 1.21 | -0.05 | -0.18 | -0.26 | -0.43 |
| Normalized Diluted EPS | 0.83 | 0.00 | -0.08 | -0.15 | -0.26 |
| Average Basic Shares Outstanding | 839.55M | 835.96M | 832.69M | 829.59M | 826.78M |
| Average Diluted Shares Outstanding | 874.30M | 862.41M | 849.43M | 835.97M | 826.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |